Actively Recruiting
Clinical Trial on the Efficacy of Intralesional Triamcinolone Versus Candida Albicans Antigen in Treating Alopecia Areata
Led by Universidad Autonoma de Nuevo Leon · Updated on 2024-08-21
30
Participants Needed
1
Research Sites
22 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the effectiveness of two intralesional treatments for alopecia areata in patients over 6 years old with less than 50% scalp involvement. This trial aims to compare the standard treatment, intralesional Triamcinolone, with a Candida albicans antigen injection to see which better improves hair loss and to monitor related side effects. Participants will receive either Triamcinolone acetonide injections at a concentration of 4 mg/mL, administered in 0.1 mL doses spaced 1 cm apart up to a maximum of 3 mL per session, or a single 0.1 mL subcutaneous injection of Candida albicans antigen into an alopecic patch. The treatments are given in a randomized, triple-masked way to fairly compare their effects. During the 5-month follow-up, participants will have clinical and trichoscopic photos taken regularly to assess treatment response and monitor any side effects. The study will carefully evaluate how each treatment affects hair regrowth and safety over this period, with all assessments conducted under medical supervision.
CONDITIONS
Brief Title
Clinical Trial on the Efficacy of Intralesional Triamcinolone Versus Candida Albicans Antigen in Treating Alopecia Areata
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of alopecia areata
- SALT score of less than 50% extension
- Has not received any topical or systemic treatment in the last month
- Signed informed consent
You will not qualify if you...
- Any skin condition on the scalp (infectious, inflammatory or neoplastic) that could modify the clinical or trichoscopic features
- Pregnancy or breast-feeding
- Patients on medications that could cause hair loss as side effects
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 5 months
Participants receive either intralesional Triamcinolone injections or a single subcutaneous Candida albicans antigen injection into alopecic patches.
Visits as needed for treatment administration and assessment
Trial Site Locations
Total: 1 location
1
Hospital Universitario "Dr. José Eleuterio González"
Monterrey, Nuevo León, Mexico, 64460
Actively Recruiting
Research Team
E
Erika Alba-Rojas, MD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here